Eyenovia, Inc. (EYEN) earnings
EYEN earnings moved a median of -3.42% by the close. Quarterly and annual EYEN reports and results, each read against the price at its own news timestamp. Back to the EYEN overview →
26 measured EYEN earnings events.
Where these EYEN earnings landedvs 21 measured EYEN earnings reactions
| Middle 50% of EYEN earnings reactions | -8.74% to 0.00% |
|---|---|
| Median reaction (to close) | -3.42% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 EYEN earnings events with a measured close landed between -8.74% and +0.00%; 24% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q HYPERION DEFI, INC. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q HYPERION DEFI, INC. For: Mar 31 | SEC filing · Form 10-Q | — | — | |
| Form 10-K HYPERION DEFI, INC. For: Dec 31 | SEC filing · Form 10-K | — | — | |
| Form 10-Q HYPERION DEFI, INC. For: Sep 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q HYPERION DEFI, INC. For: Jun 30 | SEC filing · Form 10-Q | — | — | |
| Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results | Press release | -12.22% | -7.22% | |
| Form 10-Q EYENOVIA, INC. For: Mar 31 | SEC filing · Form 10-Q | -12.22% | -7.22% | |
| Form NT 10-Q EYENOVIA, INC. For: Mar 31 | SEC filing · Form NT | -0.89% | +0.00% | |
| Form 10-K/A EYENOVIA, INC. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.68% | |
| Form 10-K EYENOVIA, INC. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -3.60% | |
| Form NT 10-K EYENOVIA, INC. For: Dec 31 | SEC filing · Form NT | +1.40% | +5.61% | |
| Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -6.42% | -12.18% | |
| Form 10-Q EYENOVIA, INC. For: Sep 30 | SEC filing · Form 10-Q | -6.42% | -12.18% | |
| Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th | Press release | +0.00% | -4.59% | |
| Form 10-Q EYENOVIA, INC. For: Jun 30 | SEC filing · Form 10-Q | -0.35% | -2.06% | |
| Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.53% | -10.30% | |
| Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th | Press release | -2.25% | -0.90% | |
| Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol | Press release | +2.79% | -3.42% | |
| Form 10-Q EYENOVIA, INC. For: Mar 31 | SEC filing · Form 10-Q | +2.79% | -3.42% | |
| Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th | Press release | -1.22% | +2.01% | |
| Form 10-K/A EYENOVIA, INC. For: Dec 31 | SEC filing · Form 10-K | -0.59% | -14.45% | |
| Form 10-K EYENOVIA, INC. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -12.96% | |
| Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th | Press release | +0.00% | -2.47% | |
| Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +1.67% | +4.17% | |
| Form 10-Q EYENOVIA, INC. For: Sep 30 | SEC filing · Form 10-Q | +1.67% | +4.17% | |
| Eyenovia to Report Third Quarter 2023 Results on Monday, November 13 | Press release | -1.01% | -8.74% |
Keep exploring
More EYEN: analyst actions → · SEC filings → · EYEN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | 267 | 0.00% | 44% |
| Galapagos NV - American Depositary Shares (GLPG) | 267 | -0.05% | 44% |
| Qiagen N.V. Common Shares (QGEN) | 266 | +0.05% | 53% |
| 22nd Century Group, Inc (XXII) | 266 | -1.87% | 30% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.